# Matrix Capital

> Matrix Capital is a VC fund in Tokyo backing Shopping, Biopharma and E-Commerce. See 3 investments, check sizes, portfolio. Updated Sep 2026.

- Type: VC Fund
- Location: Tokyo, Japan
- Total investments: 3
- Last investment: Dec 2019
- Lead investor: 33%
- Last updated: Sep 2026

Matrix Capital is a VC fund in Tokyo focused on Shopping and Biopharma. Matrix Capital Inc. is a venture capital firm. It primarily invests in the field of logistics and supply chain management. Matrix Capital Inc. was founded on April 2004 and is based in Tokyo, Japan.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Shopping | 1 | 33% |
| Biopharma | 1 | 33% |
| E-Commerce | 1 | 33% |
| Biotechnology | 1 | 33% |
| Pharmaceutical | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 67% |
| Series B | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Singapore | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Zentalis Pharmaceuticals | Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical business dedicated to finding and developing small molecule medicines that target cancer's underlying biological pathways. It employs an integrated discovery engine to find targets and produce small molecule new chemical entities, or NCEs, with features that it believes couldresult in potentially distinct product profiles. Its pipeline includes two lead product candidates: ZN-c5, which is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer, and ZN-c3, which is being developed for the treatment of advanced solid tumors as monotherapy and ovarian cancer. | $85M | Series C | Dec 09, 2019 | https://www.zentalis.com/ |
| Zentalis Pharmaceuticals | Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical business dedicated to finding and developing small molecule medicines that target cancer's underlying biological pathways. It employs an integrated discovery engine to find targets and produce small molecule new chemical entities, or NCEs, with features that it believes couldresult in potentially distinct product profiles. Its pipeline includes two lead product candidates: ZN-c5, which is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer, and ZN-c3, which is being developed for the treatment of advanced solid tumors as monotherapy and ovarian cancer. | $34M | Series B | Dec 01, 2017 | https://www.zentalis.com/ |
| Reebonz | Reebonz (瑞宝仕) is a membership-based online shopping site with a product portfolio of various luxury brands.Founded in 2009, Reebonz is headquartered in Singapore with operations in Malaysia, Thailand, Indonesia, Brunei, South Korea, Australia, New Zealand, China, Hong Kong, and Taiwan. International venture capital firms such as GGV CAPITAL,MATRIX, VERTEX VENTURE have invested in it.Reebonz offers time-limited special sales to its members, with more than 100 brands and nearly 220 newly launched and updated activities on average per month. 80% of website brands are high-end first-tier products. It guarantees that all commodities are authentic, and supports installments of assigned bank credit cards without any interest and handling charge. | $40M | Series C | May 01, 2013 | http://www.reebonz.com/event_list |

3 of 3 investments shown.

## Co-investors
- [Viking Global Investors](https://shizune.co/investors/profile/viking-global-investors) — VC Fund, 2 deals together
- [Eventide](https://shizune.co/investors/profile/eventide-asset-management) — VC Fund, 1 deal together
- [Farallon Capital Management](https://shizune.co/investors/profile/farallon-capital-management) — VC Fund, 1 deal together
- [GGV Capital](https://shizune.co/investors/profile/ggv-capital) — VC Fund, 1 deal together
- [Infocomm Investments](https://shizune.co/investors/profile/infocomm-investments) — VC Fund, 1 deal together
- [Intel Capital](https://shizune.co/investors/profile/intel-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Matrix Capital invest in?

Matrix Capital invests primarily in Shopping, Biopharma and E-Commerce startups, most often at Series C and Series B stage. Most of the 3 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Matrix Capital last invest?

The most recent investment recorded for Matrix Capital closed in Dec 2019. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co